---
title: "Centenial Surgical Suture Ltd (531380) — Share Price, Financials & Analysis"
symbol: "531380"
company: "Centenial Surgical Suture Ltd"
canonical: "https://tapetide.com/stocks/531380"
isin: "INE405H01018"
nse_symbol: "CENTENIALSURGICALSUTURELTD"
bse_code: "531380"
sector: "Healthcare"
industry: "Medical Equipment"
market_cap_cr: 35.4
generated_at: "2026-09-13T18:58:25.916Z"
---

# Centenial Surgical Suture Ltd (531380)

Canonical page: https://tapetide.com/stocks/531380

## Company

- **NSE Symbol:** CENTENIALSURGICALSUTURELTD
- **BSE Code:** 531380
- **ISIN:** INE405H01018
- **Sector:** Healthcare
- **Industry:** Medical Equipment
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** centenialindia.com

## About

Incorporated in 1995, Centenial Surgical Suture is engaged in the development, manufacturing and supply of Medical Devices.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:41:25.091070Z.

- **Market Cap:** ₹35.4 Cr
- **Classification:** Microcap
- **P/E (reported):** -24.5
- **EPS (TTM):** ₹-3.92
- **EPS (reported):** ₹2.82
- **Book Value:** ₹73.39
- **Price to Book:** 1.32
- **Dividend Yield:** 0%
- **ROE:** -7.72%
- **ROCE:** 2.61%
- **Debt to Equity:** 0.96
- **Revenue (yearly):** ₹54 Cr
- **Net Income:** ₹-2.2 Cr
- **EBITDA:** ₹5.3 Cr
- **52-Week High:** ₹124.9
- **52-Week Low:** ₹73.04
- **RSI (14):** 59.26

## Tapetide Score

- **Score:** 54 / 100
- **Score date:** 2026-09-04
- **Archetype:** Average Quality, Undemanding Price
- **What it means:** The financials sit mid-range rather than strong, and the multiple is not demanding. Nothing here stands out in either direction, so the read comes down to which single pillar you weight most and whether the next results move it off the middle.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Rising
- **Percentile:** 65.6 (of 4473 scored stocks)
- **Confidence:** 93%
- **Data coverage:** 86%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 24.7 | 9% |
| growth | 47.03 | 9% |
| momentum | 63.07 | 12% |
| ownership | 50 | 24% |
| quality | 51.62 | 22% |
| valuation | 70.41 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.82% over past five years.
- Company has a low return on equity of -2.73% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -57.35% | 17.23% | 53.26% |
| ebitda margin growth | 120% | -18.24% | -2.7% | -3.66% |
| net income growth | 130.43% | 46.67% | -300% | -466.67% |
| revenue growth | 22.22% | 0.75% | 1% | 8% |
| roce | — | -35.24% | -67.7% | 6.22% |
| roe | — | 62.18% | -2.99% | -471.15% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 13.1 | 12.38 | 12.05 | 13.74 | 14.27 | 12.2 | 13.31 | 12.94 | 13.46 | 14.86 | 12.58 | 15.34 |
| Expenses | 11.96 | 11.19 | 10.54 | 12.02 | 12.54 | 11.45 | 11.25 | 11.71 | 12.07 | 13.33 | 11.65 | 13.16 |
| Operating Profit | 1.14 | 1.19 | 1.51 | 1.72 | 1.73 | 0.75 | 2.06 | 1.23 | 1.39 | 1.53 | 0.93 | 2.18 |
| OPM % | 8.7 | 9.61 | 12.53 | 12.52 | 12.12 | 6.15 | 15.48 | 9.51 | 10.33 | 10.3 | 7.39 | 14.21 |
| Other Income | 0.02 | 0.06 | 0.03 | 0 | 0.06 | 0.01 | 0.05 | 0 | 0.05 | 0.05 | 0.07 | 0.01 |
| Interest | 0.52 | 0.51 | 0.95 | 0.53 | 0.53 | 0.5 | 2.19 | 0.32 | 0.46 | 0.35 | 2.21 | 0.29 |
| Depreciation | 0.32 | 0.33 | 0.44 | 0.79 | 1.09 | 1.11 | 1.26 | 0.95 | 0.99 | 1.04 | 1.02 | 0.92 |
| Profit before tax | 0.32 | 0.41 | 0.15 | 0.4 | 0.17 | -0.85 | -1.34 | -0.04 | -0.01 | 0.19 | -2.23 | 0.98 |
| Tax % | 28.12 | 24.39 | -26.67 | 25 | 23.53 | 0 | -11.19 | 0 | 0 | 26.32 | 4.04 | 25.51 |
| Net Profit | 0.24 | 0.31 | 0.19 | 0.3 | 0.13 | -0.85 | -1.18 | -0.04 | -0.01 | 0.15 | -2.31 | 0.74 |
| EPS in Rs | 0.66 | 0.85 | 0.52 | 0.82 | 0.36 | -2.33 | -3.23 | -0.11 | -0.03 | 0.41 | -6.33 | 2.03 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 52.73 | 56.05 | 55.61 | 36.93 | 44.43 | 52.66 | 51.19 | 53.49 | 53.81 | 56.24 |
| Expenses | 48.26 | 50.64 | 49.68 | 31.82 | 39.94 | 48.26 | 46.04 | 47.07 | 48.55 | 50.21 |
| Operating Profit | 4.47 | 5.41 | 5.93 | 5.11 | 4.49 | 4.4 | 5.15 | 6.42 | 5.26 | 6.03 |
| OPM % | 8.48 | 9.65 | 10.66 | 13.84 | 10.11 | 8.36 | 10.06 | 12 | 9.78 | 10.72 |
| Other Income | 0.05 | 0.02 | 0.09 | 0.09 | 0.04 | 0.13 | 0.13 | 0.12 | 0.17 | 0.18 |
| Interest | 1.51 | 1.89 | 2.31 | 2.12 | 1.93 | 1.77 | 2.62 | 3.9 | 3.51 | 3.31 |
| Depreciation | 0.6 | 0.69 | 1.55 | 1.55 | 1.53 | 1.3 | 1.39 | 4.25 | 4 | 3.97 |
| Profit before tax | 2.41 | 2.85 | 2.16 | 1.53 | 1.07 | 1.46 | 1.27 | -1.61 | -2.08 | -1.07 |
| Tax % | 36.1 | 29.12 | 39.81 | 37.25 | 42.06 | 39.73 | 11.02 | -9.32 | 6.25 | — |
| Net Profit | 1.54 | 2.02 | 1.3 | 0.96 | 0.63 | 0.89 | 1.13 | -1.46 | -2.2 | -1.43 |
| EPS in Rs | 4.22 | 5.54 | 3.56 | 2.63 | 1.73 | 2.44 | 3.1 | -4 | -6.03 | -3.92 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
| Reserves | 19.07 | 20.62 | 22.63 | 23.18 | 24.15 | 24.77 | 25.66 | 26.79 | 25.33 | 23.13 |
| Borrowings | 15.24 | 14.37 | 13.1 | 12.72 | 13.47 | 9.3 | 9.92 | 23.24 | 30.01 | 27.31 |
| Other Liabilities | 16.07 | 14.89 | 15.61 | 27.96 | 27 | 21.85 | 25.4 | 23.7 | 23.83 | 23.93 |
| Total Liabilities | 55.8 | 55.3 | 56.76 | 69.28 | 70.04 | 61.34 | 66.4 | 79.15 | 84.59 | 79.79 |
| Fixed Assets | 3.71 | 3.8 | 4.08 | 10.44 | 8.97 | 7.6 | 6.46 | 12.77 | 19.99 | 18.22 |
| CWIP | 0.19 | 0.22 | 0.22 | 0.22 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 51.9 | 51.28 | 52.46 | 58.62 | 61.07 | 53.74 | 59.94 | 66.38 | 64.6 | 61.57 |
| Total Assets | 55.8 | 55.3 | 56.76 | 69.28 | 70.04 | 61.34 | 66.4 | 79.15 | 84.59 | 79.79 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 1.76 | 1.55 | 2.08 | 1.97 | 4.75 | 1.3 | 6.21 | 17.07 | 7.28 |
| Cash from Investing Activity | -2.38 | -0.64 | -1.02 | -1.31 | -0.89 | -0.17 | -0.18 | -7.92 | -11.61 | -2.41 |
| Cash from Financing Activity | 2.14 | -0.88 | -1.27 | -0.37 | -1.27 | -4.87 | -1.05 | 2.06 | -5.93 | -4.89 |
| Net Cash Flow | -0.25 | 0.24 | -0.75 | 0.4 | -0.18 | -0.28 | 0.07 | 0.35 | -0.47 | -0.02 |
| Free Cash Flow | -0.66 | 1.05 | 0.57 | 1 | 1.13 | 4.59 | 1.14 | -1.49 | 5.6 | 5.05 |
| CFO/OP | 0 | 59 | 44 | 50 | 50 | 112 | 42 | 129 | 270 | 139 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 130.76 | 125.29 | 134.8 | 153.26 | 221.39 | 160.44 | 142.71 | 134.05 | 125.56 | 124 |
| Inventory Days | 468.59 | 465.89 | 434.68 | 483.86 | 1276.44 | 599.23 | 677.26 | 909.72 | 921.61 | 791.32 |
| Days Payable | 146.28 | 135.64 | 120.26 | 187.98 | 372.75 | 159 | 222.42 | 207.75 | 151.98 | 145.61 |
| Cash Conversion Cycle | 453.06 | 455.54 | 449.22 | 449.14 | 1125.08 | 600.67 | 597.56 | 836.02 | 895.19 | 769.7 |
| Working Capital Days | 156.25 | 164.05 | 167.69 | 172.36 | 282.37 | 236.68 | 207.73 | 226.67 | 210.99 | 191.69 |
| ROCE % | 11.4 | 9.78 | 11.62 | 10.84 | 8.65 | 7.27 | 8.03 | 8.07 | 3.94 | 2.45 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 51.95% | 51.71% | 51.68% | 50.21% | 50.21% | 50.2% | 50.29% | 50.29% | 50.64% | 50.7% | 50.69% | 50.71% |
| Others | 1.16% | 1.4% | 1.43% | 2.9% | 2.9% | 2.91% | 2.83% | 2.82% | 2.47% | 2.41% | 2.43% | 2.4% |
| No. of Shareholders | 947 | 1016 | 1072 | 1159 | 1163 | 1186 | 1206 | 1186 | 1193 | 1200 | 1182 | 1165 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 7 / 0

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 92.95 | Buy |
| EMA (10) | 93.46 | Buy |
| SMA (20) | 92.46 | Buy |
| EMA (20) | 91.59 | Buy |
| SMA (50) | 84.8 | Buy |
| EMA (50) | 88.54 | Buy |
| SMA (100) | 87.28 | Buy |
| EMA (100) | 89.48 | Buy |
| SMA (200) | 93.73 | Buy |
| EMA (200) | 95.9 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 59.26 | Neutral |
| MACD (12,26,9) | 2.51 | Buy |
| Stochastic (14,3,3) | 53.69 | Neutral |
| ADX (14) | 14.21 | Neutral |
| Williams %R (14) | -35.36 | Neutral |
| ATR (14) | 4.15 | High Volatility |
| ROC (12) | 4.52 | Buy |
| Stoch RSI (14) | 72.47 | Neutral |
| UO (7,14,28) | 42.32 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7 Feb - Board meeting on Feb 12, 2026 to approve standalone unaudited results for quarter and nine months ended Dec 31, 2025. | [Board Meeting Intimation for As Per Reg 29 Of SEBI (LODR) Regulations, 2015 For Approval Of Standalone Un-Audited Financial Results For The Quarter Ended December 31, 2025 As Per Reg 33 Of The SEBI (LODR) Regulations, 2015 7 Feb - Board meeting on Feb 12, 2026 to approve standalone unaudited results for quarter and nine months ended Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a3cec2ae-e0d5-42f7-8ca3-970ed4aaf369.pdf) |
| 29 Apr - Centenial Surgical Suture says it is not a Large Corporate under SEBI circular, dated April 29, 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 29 Apr - Centenial Surgical Suture says it is not a Large Corporate under SEBI circular, dated April 29, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/92ed2144-e8a9-4006-9312-5bf0832d8340.pdf) |
| 29 Apr - Centenial Surgical Suture says it is not a Large Corporate under SEBI circular, dated April 29, 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 29 Apr - Centenial Surgical Suture says it is not a Large Corporate under SEBI circular, dated April 29, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/92ed2144-e8a9-4006-9312-5bf0832d8340.pdf) |
| 27 Mar - Trading window closed from April 1, 2026 until 48 hours after results for March 31, 2026. | [Closure of Trading Window 27 Mar - Trading window closed from April 1, 2026 until 48 hours after results for March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/723c87ee-5533-49a2-9f1f-41965dc8dd67.pdf) |
| 17 Mar - Company reports unusual price movement, alleges possible price rigging; requests BSE/SEBI probe (scrip 531380, Mar 17, 2026). | [Clarification On Price Movement 17 Mar - Company reports unusual price movement, alleges possible price rigging; requests BSE/SEBI probe (scrip 531380, Mar 17, 2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ac3fe98d-03bf-44ab-a9a6-e700e01a969b.pdf) |
| 17 Feb - Alleged manipulative trading in Centenial Surgical Suture Ltd (scrip 531308), Feb 6–13, 2026; annexure provided. | [Urgent Attention For Possible MISUSE / UNETHICAL / UNUSUAL TRADES In Our Company Scrip. 17 Feb - Alleged manipulative trading in Centenial Surgical Suture Ltd (scrip 531308), Feb 6–13, 2026; annexure provided.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2d202209-f9cc-40d6-96a0-c278bdf5ee3d.pdf) |
| 14h - Centenial Surgical Suture seeks BSE probe into abnormal price movement in scrip 531380 on May 11, 2026. | [Price Movement 14h - Centenial Surgical Suture seeks BSE probe into abnormal price movement in scrip 531380 on May 11, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/dee436dd-7dd8-41fc-a30c-1ce922ec47a8.pdf) |
| 12 Feb - Standalone unaudited results and limited review for quarter/nine months ended Dec 31, 2025 filed Feb 12, 2026. | [Standalone Un-Audited Financial Results For The Quarter And Nine Months Ended December 31, 2025 12 Feb - Standalone unaudited results and limited review for quarter/nine months ended Dec 31, 2025 filed Feb 12, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9d3cf988-67a9-4dac-aa2e-b5cb14ade24e.pdf) |
| 12 Feb - Approved standalone unaudited results for quarter and nine months ended Dec 31, 2025 (Feb 12, 2026). | [Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday, February 12, 2026 Pursuant To Regulation 30 Read With Schedule III(A)(IV) Of The SEBI (LODR [LODR]) Regulations, 2015. 12 Feb - Approved standalone unaudited results for quarter and nine months ended Dec 31, 2025 (Feb 12, 2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2a048daf-d546-4776-ba7d-503c184c6297.pdf) |
| 11 Sep - Anuradha Kashikar resigned and Sapna Mhatre appointed CFO effective August 14, 2026. | [Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) 11 Sep - Anuradha Kashikar resigned and Sapna Mhatre appointed CFO effective August 14, 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f2ccba53-5df9-414d-9260-266a3f83b56d.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6715e74-9409-481d-a80c-f85982da3012.pdf) |
| 2026-09-01 | [Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 In Terms Of The Requirements Of Regulation 36(1)(B) - Letter Issued To Non-Emailholders Providing The Web-Link From Where The Notice Of 31St AGM & Annual Report For The FY 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68a51862-4c9c-43de-87b4-525ef0cc71cd.pdf) |
| 2026-09-01 | [Intimation Of AGM & Submission Of Notice Of 31St AGM To Be Held On Monday September 28 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb2997d8-04ed-40de-b7ec-bd4adcf5b483.pdf) |
| 2026-09-01 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=88bd07e3-ace1-41e3-a8ee-2c32b2bc0230.pdf) |
| 2026-08-26 | [Price Of The Scrip Of Our Company Has Seen An Abnormal Price Rise](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d43b0eb8-35c1-4a2e-9994-d3d64428d62c.pdf) |
| 2026-08-17 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e40a890b-1c18-46cb-ad76-74eaa23beed7.pdf) |
| 2026-08-14 | [Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday August 14 2026 Pursuant To Regulation 30 Read With Schedule III(A)(IV) Of The SEBI (Listing Obligations And Disclosure Requirements [LODR]) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65176536-6aad-4bb4-8aec-3de70dbaaabd.pdf) |
| 2026-08-14 | [Intimation Of Appointment Of Internal Auditor - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69224902-8e99-47e1-b886-3ab426543207.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94152f75-8d28-4304-a5e9-da3cb014b357.pdf) |
| 2026-08-14 | [Re-Appointment Of Whole Time Director Of The Company - Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (The SEBI Listing Regulation).](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f8ae1b0-fad9-49b5-a5d0-d56c639a4494.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Approval Of Standalone Un-Audited Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fd3cff27-9bf2-44f7-b63b-19050650d7d4.pdf) |
| 2026-05-30 | [Approval Of Standalone Audited Financial Results For The Quarter And Year Ended March 31 2026 Along With Declaration And AuditorS Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6de832f1-f5ab-4672-aba8-32d5cc49d100.pdf) |
| 2026-02-12 | [Standalone Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d3cf988-67a9-4dac-aa2e-b5cb14ade24e.pdf) |
| 2025-11-13 | [Standalone Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dbba9f1d-adc3-4a09-8ca6-8d18cbefddc1.pdf) |
| 2025-08-12 | [Standalone Un-Audited Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2070f16-129e-46f9-8ece-de9a1a0e3a17.pdf) |
| 2025-05-28 | [Standalone Audited Financial Results For The Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e84fb22-d3ed-4252-a207-02f902a992e9.pdf) |
| 2025-02-14 | [Standalone Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f45635e9-e69e-4028-82e5-2789201f12f7.pdf) |
| 2024-11-14 | [Standalone Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8649e9d-c82a-4598-943a-d6a7fc64f265.pdf) |
| 2024-08-12 | [Standalone Un-Audited Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec337410-db45-483c-860c-2b2ef950428e.pdf) |
| 2024-05-28 | [Standalone Audited Financial Results For The Quarter And Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87b9d939-7c3c-4eed-90e7-bbe60967d987.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/01791771-f40a-466e-8ae4-547f17570343.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/667048c6-7811-4a7c-bc44-873102864b29.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b666fe6e-b656-46d1-bd6a-374ef9dc5262.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/531380/73721531380.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/531380/70393531380_04_09_21.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/531380/65536531380.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/531380/5313800319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/531380/5313800318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/531380/5313800317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/531380/5313800316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:58:25.916Z.